Sanofi, Generics Failed To Report Ambien IP Deals: FTC

Law360, New York (May 10, 2011, 10:11 PM EDT) -- The Federal Trade Commission said on Tuesday that Sanofi-Aventis U.S. LLC and two generic-drug makers violated federal law by failing to report patent infringement pacts that resolved suits over Sanofi’s Ambien CR, but the companies were let off with a warning.

The FTC’s Bureau of Competition sent advisory letters to Sanofi, Watson Pharmaceuticals Inc., and Synthon Holding BV on Monday notifying the companies that the regulatory agency had recommended no enforcement action.

The FTC revealed that the settlements in question had not harmed consumers or competition,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.